Protectin DX ameliorates palmitate‐induced hepatic insulin resistance through AMPK/SIRT1‐mediated modulation of fetuin‐A and SeP expression. (21st July 2019)
- Record Type:
- Journal Article
- Title:
- Protectin DX ameliorates palmitate‐induced hepatic insulin resistance through AMPK/SIRT1‐mediated modulation of fetuin‐A and SeP expression. (21st July 2019)
- Main Title:
- Protectin DX ameliorates palmitate‐induced hepatic insulin resistance through AMPK/SIRT1‐mediated modulation of fetuin‐A and SeP expression
- Authors:
- Jung, Tae Woo
Ahn, Sung Ho
Shin, Jong Wook
Kim, Hyoung‐Chun
Park, Eon Sub
Abd El‐Aty, A. M.
Hacımüftüoğlu, Ahmet
Song, Ki Hak
Jeong, Ji Hoon - Abstract:
- Abstract: The role as well as the molecular mechanisms of protectin DX (PDX) in the prevention of hepatic insulin resistance, a hallmark of type 2 diabetes, remains unknown. Therefore, the present study was designed to explore the direct impact of PDX on insulin resistance and to investigate the expression of fetuin‐A and selenoprotein P (SeP), hepatokines that are involved in insulin signalling, in hepatocytes. Human serum levels of PDX as well as fetuin‐A and SeP were determined by high‐performance liquid chromatography (HPLC). Human primary hepatocytes were treated with palmitate and PDX. NF‐κB phosphorylation as well as expression of insulin signalling associated genes and hepatokines were determined by Western blotting analysis. FOXO1 binding levels were measured by quantitative real‐time PCR. Selected genes from candidate pathways were evaluated by small interfering (si) RNA‐mediated gene suppression. Serum PDX levels were significantly ( P < 0.05) downregulated, whereas serum fetuin‐A and SeP levels were increased ( P < 0.05) in obese subjects compared with healthy subjects. In in vitro experiments, PDX treatment increased AMP‐activated protein kinase (AMPK) phosphorylation and SIRT1 expression and attenuated palmitate‐induced fetuin‐A and SeP expression and insulin resistance in hepatocytes. AMPK or SIRT1 siRNA mitigated the suppressive effects of PDX on palmitate‐induced fetuin‐A through NF‐κB and SeP expression linked to FOXO1 and insulin resistance.Abstract: The role as well as the molecular mechanisms of protectin DX (PDX) in the prevention of hepatic insulin resistance, a hallmark of type 2 diabetes, remains unknown. Therefore, the present study was designed to explore the direct impact of PDX on insulin resistance and to investigate the expression of fetuin‐A and selenoprotein P (SeP), hepatokines that are involved in insulin signalling, in hepatocytes. Human serum levels of PDX as well as fetuin‐A and SeP were determined by high‐performance liquid chromatography (HPLC). Human primary hepatocytes were treated with palmitate and PDX. NF‐κB phosphorylation as well as expression of insulin signalling associated genes and hepatokines were determined by Western blotting analysis. FOXO1 binding levels were measured by quantitative real‐time PCR. Selected genes from candidate pathways were evaluated by small interfering (si) RNA‐mediated gene suppression. Serum PDX levels were significantly ( P < 0.05) downregulated, whereas serum fetuin‐A and SeP levels were increased ( P < 0.05) in obese subjects compared with healthy subjects. In in vitro experiments, PDX treatment increased AMP‐activated protein kinase (AMPK) phosphorylation and SIRT1 expression and attenuated palmitate‐induced fetuin‐A and SeP expression and insulin resistance in hepatocytes. AMPK or SIRT1 siRNA mitigated the suppressive effects of PDX on palmitate‐induced fetuin‐A through NF‐κB and SeP expression linked to FOXO1 and insulin resistance. Recombinant fetuin‐A and SeP reversed the suppressive effects of fetuin‐A and SeP expression on palmitate‐mediated impairment of insulin signalling. The current finding provides novel insight into the underlying mechanism linking hepatokines to the pathogenesis of hepatic insulin resistance. … (more)
- Is Part Of:
- Clinical and experimental pharmacology and physiology. Volume 46:Number 10(2019)
- Journal:
- Clinical and experimental pharmacology and physiology
- Issue:
- Volume 46:Number 10(2019)
- Issue Display:
- Volume 46, Issue 10 (2019)
- Year:
- 2019
- Volume:
- 46
- Issue:
- 10
- Issue Sort Value:
- 2019-0046-0010-0000
- Page Start:
- 898
- Page End:
- 909
- Publication Date:
- 2019-07-21
- Subjects:
- AMPK -- fetuin‐A -- hepatocytes -- protectin DX -- selenoprotein P -- SIRT1
Clinical pharmacology -- Periodicals
Pharmacology, Experimental -- Periodicals
Physiology, Experimental -- Periodicals
Physiology, Pathological -- Periodicals
615.1 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=cep ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1440-1681.13131 ↗
- Languages:
- English
- ISSNs:
- 0305-1870
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.252000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11670.xml